Just over a month ago, at the BIO virtual conference, Pfizer Commercial Director John Young said the company was not thinking of a return on investment for its rapidly developing COVID-19 vaccine. Instead, he said, “finding medical solutions to this crisis” was a Pfizer priority. But now that the company …
Read More »
Johnson & Johnson, like all drug makers in the COVID-19 vaccine race, hopes to muster enough manufacturing capacity to rapidly scale production of its vaccine. Now, for a sum of nearly half a trillion dollars, J&J is ready to put his money where his mouth is. J&J and Maryland-based CDMO …
Read More »
In the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to test rheumatoid arthritis with Kevzara in desperately ill patients. But after the first warning signs, a phase 3 failure has forced drug makers to make their judgment in the United States. Sanofi and Regeneron …
Read More »
German vaccine maker CureVac has lost some shine in the race for a COVID-19 vaccine after other mRNA-based applicants have caught the attention of regulators. Still, CureVac is reported to have caught a great partner to help build its game-changing RNA “printers” that could turn global interest in its favor. …
Read More »
In the month ending April 7, 423 cancer patients at Memorial Sloan Kettering Cancer Center were diagnosed with COVID-19, 20% of whom developed severe respiratory symptoms. That in itself was not surprising, given that cancer patients are immunocompromised and therefore face an increased risk of fighting the virus. But a …
Read More »